Literature DB >> 7973432

Mucosal interleukin-6 secretion in ulcerative colitis. Effects of anti-inflammatory drugs and T-cell stimulation.

S C Jones1, J E Crabtree, B J Rembacken, M F Dixon, L K Trejdosiewicz, J T Whicher, A T Axon.   

Abstract

BACKGROUND: We have studied modulation of mucosal interleukin-6 (IL-6) secretion by T-cell activation and by anti-inflammatory agents in inflammatory bowel disease.
METHODS: In vitro secretion of IL-6 by biopsy specimens from patients with active ulcerative colitis was investigated in the presence of cyclosporin-A (CsA) and drugs that have other anti-inflammatory actions. Biopsy specimens from patients with quiescent ulcerative colitis or controls were stimulated with anti-CD3 antibody to activate mucosal T cells.
RESULTS: Stimulation of control specimens increased IL-6 secretion (median increase, 147%; p < 0.003), which was prevented by CsA. In quiescent ulcerative colitis there was enhanced spontaneous secretion of IL-6 but a smaller, non-significant increase after T-cell activation (125%). Dexamethasone inhibited secretion in active ulcerative colitis (p < 0.006). 5-Aminosalicylic acid, 6-mercaptopurine, methotrexate, and indomethacin had no effect. There also tended to be a small reduction with CsA, but this just failed to reach statistical significance.
CONCLUSIONS: In quiescent ulcerative colitis the enhanced spontaneous secretion of IL-6 may be a consequence of mucosal T-cell or macrophage activation: the smaller increase after T-cell stimulation suggests that one or both of these two cell types are already pre-activated.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7973432     DOI: 10.3109/00365529409092500

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  7 in total

1.  A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease.

Authors:  K Mitsuyama; N Tomiyasu; A Suzuki; K Takaki; H Takedatsu; J Masuda; H Yamasaki; S Matsumoto; O Tsuruta; A Toyonaga; M Sata
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

2.  Local and systemic liberation of proinflammatory cytokines in ulcerative colitis.

Authors:  M Gotteland; M Lopez; C Muñoz; R Saez; H Altshiller; P Llorens; O Brunser
Journal:  Dig Dis Sci       Date:  1999-04       Impact factor: 3.199

Review 3.  Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer.

Authors:  Raja Atreya; Markus F Neurath
Journal:  Clin Rev Allergy Immunol       Date:  2005-06       Impact factor: 8.667

4.  Colonic explant production of IL-1and its receptor antagonist is imbalanced in inflammatory bowel disease (IBD).

Authors:  S Dionne; I D D'Agata; J Hiscott; T Vanounou; E G Seidman
Journal:  Clin Exp Immunol       Date:  1998-06       Impact factor: 4.330

5.  Abnormal function of platelets and role of angelica sinensis in patients with ulcerative colitis.

Authors:  Wei-Guo Dong; Shao-Ping Liu; Hai-Hang Zhu; He-Sheng Luo; Jie-Ping Yu
Journal:  World J Gastroenterol       Date:  2004-02-15       Impact factor: 5.742

6.  Mucosal expression of interleukin-6 and interleukin-8 messenger RNA in ulcerative colitis and in Crohn's disease.

Authors:  F Arai; T Takahashi; K Furukawa; K Matsushima; H Asakura
Journal:  Dig Dis Sci       Date:  1998-09       Impact factor: 3.199

7.  Human intestinal epithelial and smooth muscle cells are potent producers of IL-6.

Authors:  Edmond K Ng; Ninder Panesar; Walter E Longo; Marc J Shapiro; Donald L Kaminski; Kym C Tolman; John E Mazuski
Journal:  Mediators Inflamm       Date:  2003-02       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.